JNJ, NVS, AMGN, and GILD are a few names where such a deal is conceivable. PFE could be candidate if they divested their PD-L1 program co-owned by Merck KGaA. MRK and Roche can probably be ruled out due to their competing I-O programs.
Buyout vig is not the main reason I added to BMY on Friday (#msg-128020995), but it's another reason to like the stock at the current valuation.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.